Related Experiment Video
Updated: Jun 7, 2025
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
Unraveling Glioblastoma: TME Implication and Gene Therapy Advances
1Department of Biotechnology, School of Biosciences & Technology, VIT University, Vellore Dt. PIN:632014, India.
Abstract:
Glioblastoma is a malignant manifestation of a solid brain tumour with a very dismal prognosis due to an overall median survival of 14 months. The currently administered Standard treatment plan, the STUPP regimen, is not very effective in tackling this neoplasia. A major concern that affects the development of new drug formulations, specifically for Glioma, is the inherent sub-clonal heterogeneity, which includes the dynamic and intricate nature of the Tumour Microenvironment (TME). Targeting the cellular niche using personalized medication for glioma specifically gene therapy, seems to be promising, with most studies in preclinical models yielding optimistic results. This paper analyses the great headways made in glioma gene therapy in the last 10 years while looking into different therapeutic strategies. That said, certain challenges do plague the clinical use of gene therapy which have been highlighted in the hopes that future researchers will address these concerns and further propel gene therapy in its journey from the Lab to the bedside.
Insights
Gene therapy shows promise for treating malignant glioma, a brain tumor with poor survival rates. This review highlights advancements and challenges in glioma gene therapy over the past decade.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Genetics
Background:
- Glioblastoma is an aggressive brain tumor with a median survival of only 14 months.
- Current treatments like the STUPP regimen have limited efficacy.
- Sub-clonal heterogeneity and the tumor microenvironment (TME) complicate drug development for glioma.
Purpose of the Study:
- To review advancements in glioma gene therapy over the last 10 years.
- To analyze various therapeutic strategies for glioma.
- To identify challenges hindering clinical translation of gene therapy for brain tumors.
Main Methods:
- Comprehensive literature review of preclinical and clinical studies on glioma gene therapy.
- Analysis of therapeutic approaches targeting glioma heterogeneity and TME.
- Identification of key challenges and future research directions.
Main Results:
- Gene therapy demonstrates optimistic results in preclinical glioma models.
- Personalized gene therapy targeting the tumor niche shows potential.
- Significant progress has been made in developing novel gene therapy strategies.
Conclusions:
- Glioma gene therapy is a promising field with substantial recent advancements.
- Overcoming challenges related to tumor heterogeneity and TME is crucial for clinical success.
- Further research is needed to translate promising preclinical findings into effective patient treatments.
More Related Videos
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Related Concept Videos
02:17The Tumor Microenvironment
01:29Microorganisms in Medicine and Therapeutics
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
00:59Gene Therapy